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Eccrine porocarcinoma (EPC) was first described by 
Pinkus & Mehregan in 1963 (1) as “epidermotropic 
eccrine carcinoma” and is the malignant counterpart 
of eccrine poroma. It is a rare tumour (0.005–0.01% 
(2, 3) of cutaneous tumours), thought to arise from the 
acrosyringium of the sweat gland of the skin. The term 
“porocarcinoma” was first used by Mishima & Morioka 
in 1969 (4). Although initial case series suggested that 
this was a highly aggressive tumour, with approximately 
60% of cases reported to have local recurrence,  metas-
tases or death, later larger case series of 18, 24 and 27 
patients, respectively, did not support such an aggressive 
natural history (3, 5, 6)
The largest case series to date (69 cases) in 2001 (7), 
reported EPC as a less aggressive tumour, with 17% local 
recurrence, 19% lymph node metastasis and 11% distant 
metastases or death. 
This study analysed the age-standardised incidence 
rates for the population of the East of England (East Nor-
folk and Waveney), and estimated the numbers of cases 
likely to be found here and in the UK for 2020, 2025 and 
2030. This cohort (n = 152) is the largest reported so far 
and there are long-term follow-up data for recurrences, 
metastases and survival/death, thus helping to clarify the 
natural history of this tumour.
METHODS
Electronic databases from the pathology department at the Norfolk 
and Norwich University Hospital (NNUH) from East Norfolk 
and Waveney (ENW): (Breckland, Broadland, Great Yarmouth, 
North Norfolk, Norwich, South Norfolk and Waveney community 
districts) in the Eastern Region of the UK (population: 794,043 in 
2004 increasing to 870,100 in 2013) (8–11), were analysed and 
collected from the 1st of January, 2004 to 31st December 2013 for 
this retrospective cohort analyses. 
Skin cancer histology results from each hospital in the region 
are coded and recorded monthly by the International Classification 
of Diseases categories ICD10/ICDO-2.
There have been no changes in catchment area for the pathology 
laboratory or change in practice protocols or routines for the pa-
thologists and laboratory involved for the period of study. There 
have been no changes in physician patterns of referral of lesions 
over the study period. Standard immunohistochemical stains for 
markers known to be helpful in diagnosis of EPC such as epithelial 
membrane antigen (EMA), carcino-embryonic antigen (CEA), 
CD117 (KIT), etc, have been used as required or as available. 
Specialist dermatopathologists in the NNUH led the routine ana-
lyses of skin specimens. All porocarcinoma in situ samples were 
excluded from analyses. Only patients with verified survival and 
recurrence data were included in the study.
Statistical analyses were performed using statistics package 
GraphPad™ Prism 7 (2016).
RESULTS
Over the 10-year study period stated above, the popula-
tion of ENW increased by approximately 10.4% at a 
steady rate (8–11). Our recorded data for the numbers of 
EPC from the study period are shown in Fig. 1. Based on 
these data, linear regression analyses estimate numbers 
of cases for the years 2020 (n = 54), 2,025 (n = 71) and 
2,030 (n = 88).  
The East of England has a higher number of the el-
derly (> 65 years of age), Caucasians (White) and more 
sunshine per annum by comparison with the UK mean. 
The technique of approximation to the means (8–10) 
controlled for these risk factors and extrapolated regional 
ENW data to UK levels, this allowed estimation of the 
national incidence in future years. 
The predicted total number of cases of EPC for the 
whole of the UK was 2,979 in 2020, 3,873 in 2025 and 
4,746 in 2030. [These figures are calculated estimates 
only, and the risk of error increases the further away the 
estimate is made (see Fig. 1)].
The Age-Standardised Incidence (ASI) Rates for EPC 
in males, females and the total population of the East of 
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Fig. 1. Number of cases of eccrine porocarcinoma diagnosed in 
East Norfolk and Waveney, with predicted cases in 2020, 2025 and 
2030. Total no. of cases per year were 1, 5, 5, 11, 14, 13, 14, 31, 28, 30 
for the data points shown below from 2004–2013.
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England was calculated using the European Standard 
Population 2013 (Table SI1). This allowed comparison 
of these incidence rates with that of other published data 
so far. The ASI for males was 2.414 per 100,000, the ASI 
for females was 1.344 per 100,000 and the Total ASI was 
1.866 per 100,000. These data showed that the incidence 
of diagnosed EPC in the East of England has increased 
rapidly over the 10-year study period. The rates of EPC 
are very high at the end of the study period, > 30-fold 
higher than that published for skin adnexal tumours as 
a whole in Holland (12),  or  nearly 10-fold higher than 
for Minnesota in the US (13).
Long-term follow-up data for these patients showed 
that the rates for metastases and recurrences are 16.45% 
and disease-specific deaths (DSD) were 7.89% (males: 
6, and females: 6). Combined rates for total metastases/
recurrences (males: 16, females: 9) and DSD would be 
17.11%. These rates are not dissimilar to those reported 
by Robson et al. 2001 (7).
DISCUSSION
EPC is a rare malignancy originating from the acrosy-
ringium of the sweat gland. Early studies reported that 
the tumour was highly aggressive with 60% rates of 
recurrences, metastases or death. This study presents 
possibly the largest cohort of patients with EPC (n = 152) 
over a 10-year period, and therefore might show slightly 
more accurate analyses of natural history.
These data show that although EPC appears to be a 
more aggressive tumour than squamous cell carcinoma 
(SCC) of the skin (mortality ~1%) on a per case basis, the 
mortality rate of nearly 8% is not as high as that initially 
reported by smaller case series. 
We have previously shown that there has been a rapid 
rise in the UK incidence of non-melanoma skin cancers 
such as basal cell carcinomas, SCCs, and Merkel cell 
carcinoma (8–10). These data demonstrate that EPC in-
cidence is also rising rapidly.  The data show that EPC is 
a cancer of the elderly, with a median age of 82 in males, 
86.5 in females, a male to female ratio of 1.7:1 and the 
highest ASIs are in the over 85s in both sexes.
The reasons for the rapid rise in incidence rates are 
unclear. It is likely that contributory factors include an 
increased efficiency and accuracy in histological diag-
nosis with better histological discrimination of EPC 
from poorly defined SCC of skin.  The use of specific 
immunostains reported to be useful in the diagnosis of 
EPC such as CEA, EMA, PAS staining for glycogen, and 
CD117 may also be a contributory factor. Historical less 
efficient registration practices may also play a part. This 
study identified a much higher incidence rate at the end 
of the study period than available US or European data. 
In addition to diagnostic factors, genetic factors and the 
rise in sun-seeking holidays taken by the largely pale 
skinned UK population over the last 30–40 years may 
also be contributory.  
In conclusion, we show that (i) EPC diagnosis, al-
though rare, has been rising in the East of England, and 
has risen rapidly over the last 10 years, possibly due to 
histological diagnostic factors, and more precise registra-
tion together with a possible real increase in incidence; 
(ii) The EPC ASIs are much higher than the scanty data 
available from other Western countries, and it is likely 
that the incidence is also high in the rest of the UK; (iii) 
EPC is a more aggressive tumour compared to SCC of 
the skin but the metastases and mortality rates are not as 
high as early reports suggested.
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Table SI. Computation of age-standardized incidence rates (Eccrine Porocarcinoma, ENW, 2004–2013 
using the European Standard Population 2013) 
Age Group 
i 
No. of 
cases 
di 
Person-years 
at risk 
yi
Age-specific incidence 
(per 105 years) 
105(di/yi) 
European Standard 
Population 
wi 
Expected cases in 
standard population 
diwi/yi 
Males
0–4 years 0 216,076 0 5,000 0
5–9 years 0 214,629 0 5,500 0
10–14 years 0 235,488 0 5,500 0
15–19 years 0 245,676 0 5,500 0
20–24 years 0 237,688 0 6,000 0
25–29 years 0 225,091 0 6,000 0
30–34 years 0 224,422 0 6,500 0
35–39 years 0 254,346 0 7,000 0
40–44 years 0 279,615 0 7,000 0
45–49 years 0 271,573 0 7,000 0
50–54 years 0 253,874 0 7,000 0
55–59 years 2 264,724 0.756 6,500 0.049
60–64 years 1 274,074 0.365 6,000 0.022
65–69 years 7 239,547 2.922 5,500 0.161
70–74 years 16 195,768 8.173 5,000 0.409
75–79 years 11 156,477 7.030 4,000 0.281
80–84 years 24 109,280 21.962 2,500 0.549
85+ years 35   78,585 44.54 2,500 1.113
Total 96 3,976,933 100,000 2.414
Females
0–4 years 0 205,081 0 5,000 0
5–9 years 0 205,365 0 5,500 0
10–14 years 0 224,790 0 5,500 0
15–19 years 0 238,970 0 5,500 0
20–24 years 0 236,206 0 6,000 0
25–29 years 1 222,720 0.449 6,000 0.027
30–34 years 0 226,310 0 6,500 0
35–39 years 0 257,919 0 7,000 0
40–44 years 0 284,758 0 7,000 0
45–49 years 0 278,248 0 7,000 0
50–54 years 0 265,098 0 7,000 0
55–59 years 0 280,277 0 6,500 0
60–64 years 0 287,288 0 6,000 0
65–69 years 1 247,956 0.403 5,500 0.022
70–74 years 12 209,894 5.717 5,000 0.286
75–79 years 8 185,257 4.318 4,000 0.173
80–84 years 10 151,969 6.580 2,500 0.165
85+ years 34 159,522 21.314 2,500 0.533
Total 56 4,167,628 100,000 1.344
Whole population
0–4 years 0 421,157 0 5,000 0
5–9 years 0 419,994 0 5,500 0
10–14 years 0 460,278 0 5,500 0
15–19 years 0 484,646 0 5,500 0
20–24 years 0 473,894 0 6,000 0
25–29 years 1 447,811 0.223 6,000 0.013
30–34 years 0 450,732 0 6,500 0
35–39 years 0 512,265 0 7,000 0
40–44 years 0 564,373 0 7,000 0
45–49 years 0 549,821 0 7,000 0
50–54 years 0 518,972 0 7,000 0
55–59 years 2 545,001 0.367 6,500 0.024
60–64 years 1 561,362 0.178 6,000 0.011
65–69 years 8 487,503 1.641 5,500 0.090
70–74 years 18 405,662 4.437 5,000 0.222
75–79 years 19 341,734 5.560 4,000 0.222
80–84 years 34 261,249 13.014 2,500 0.325
85+ years 69 238,107 28.979 2,500 0.724
Total 152 8,144,561 100,000 1.866
